{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.3","value":"17.4"},{"groupId":"OG001","spread":"6.52","value":"12.8"}]}],"title":"Gemcitabine: Week 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.0","value":"10.3"},{"groupId":"OG001","spread":"9.26","value":"10.6"}]}],"title":"dFdU: Week 0"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"description":"Cmax was defined as maximum observed urine concentration.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with CIS with or without papillary disease, received TAR-200 intravesically every 3 weeks (Q3W) from Week 0 for the first 24 weeks, followed by every 12 weeks (Q12W) dosing through Week 99 in combination with cetrelimab 360 milligrams (mg) intravenously (IV) Q3W from Week 0 through Week 78. TAR-200 was inserted intravesically via the urinary placement catheter (UPC).","id":"OG000","title":"Cohort 1: TAR-200 + Cetrelimab (CIS With or Without Papillary Disease)"},{"description":"Participants with CIS with or without papillary disease, received TAR-200 intravesically Q3W from Week 0 for the first 24 weeks, followed by Q12W dosing through Week 99. TAR-200 was inserted intravesically via UPC.","id":"OG001","title":"Cohort 2: TAR-200 Monotherapy (CIS With or Without Papillary Disease)"}],"paramType":"MEAN","populationDescription":"FAS included all enrolled participants who received at least 1 dose of study treatment. Here \"N\" (overall number of participants analyzed) signifies number of participants evaluable for this outcome measure. This OM was planned to be analyzed for Cohorts 1 and 2 only.","reportingStatus":"POSTED","timeFrame":"At Week 0","title":"Cohorts 1 and 2: Maximum Observed Urine Concentration (Cmax) of Gemcitabine and dFdU (Metabolite)","type":"SECONDARY","unitOfMeasure":"mcg/mL"}